We encourage prospective D/P's (donor/participants) to become involved in current and future studies. If a study listed does not apply to your particular situation we still invite you to register so that we may include you in our database and contact you for future studies.
We are looking for D/P's in the following categories:
| ID # | Required D/P's | Enrolled D/P's | Remaining D/P's | Inclusion Criteria |
|---|---|---|---|---|
| 235480 | 19 | 20 | -1 | Pre-Selected Chlamydia Positive Samples from Inventory (Serum and Plasma) |
| 235406 | 300 | 74 | 226 | SARS-CoV-2 RNA Hologic Testing (Felix Chao and Peter Kim) |
| 235321 | 1 | 0 | 1 | Fresh Whole Blood from Healthy Donor(s) |
| 235306 | 6 | 6 | 0 | Pre-Selected HxV Negative Samples from Inventory |
| 235301 | 6 | 5 | 1 | Pre-Selected HIV Samples from Inventory with Viral Load and Specific Mutation |
| 235121 | 15 | 15 | 0 | Double Spun Plasma from Healthy (HxV Negative) D/Ps - INC4581474/ SACQ_0002410 |
| 235115 | 24 | 0 | 24 | Female Vaginal Sample Collection Protocol for Panel Development |
| 234803 | 200 | 0 | 200 | Collection protocol for Panel construction (Custom HIV-1 Matched sets panels, Q_16976) |
| 234476 | 3 | 6 | -3 | Prospective SARS-CoV-2 Negative Raw Saliva Samples - OR21-265 |
| 234348 | 5 | 5 | 0 | Pre-Selected HIV Samples from Inventory with Viral Load |
| 234347 | 5 | 5 | 0 | Pre-Selected HCV Positive Samples from Inventory with HCV Viral Load |
| 234090 | 17 | 33 | -16 | Pre-Selected anti-HBs Positive Samples from Inventory |
| 234079 | 240 | 30 | 210 | Prospective Whole Blood Collection from HxV Negative D/Ps |
| 233572 | 1000 | 2542 | -1542 | Disposition of BioRepository Samples - Negatives Covid Swabs |
| 233409 | 12 | 4 | 8 | Pre-Selected HCV Positive Samples form Inventory (K2EDTA and/or Citrate Plasma) |
| 233408 | 12 | 14 | -2 | Pre-Selected HBV Positive Samples form Inventory |
| 233218 | 150 | 8 | 142 | IDS-21MAXCOMBO - SARS-CoV-2 Hologic Aptima Testing |
| 233007 | 1000 | 27 | 973 | CBC Initiative, SACQ_0002392 (INC4932295) - SRF_0002617 - Buffy Coat - BCW |
| 232963 | 8 | 8 | 0 | Buffy Coat from Healthy D/Ps with Specific WBC Count - INC4932295 |
| 232619 | 8 | 8 | 0 | HIV Positive Stability Study |
| 231875 | 5 | 5 | 0 | Fresh Whole Blood from Healthy (HxV Negative) D/Ps - INC4687934_2 |
| 231769 | 10 | 11 | -1 | Pre-screening protocol (HIV Viral Load)Samples to be tested in Abbott for Raquel (Cepheid) request |
| 231541 | 14 | 14 | 0 | SARS-CoV-2 Fresh Negative Nasopharyngeal Swabs and Nasal Swabs (Copan & Remel) - OR21-247 |
| 231203 | 50 | 0 | 50 | Vaginal Swab Samples From Subjects With Suspected STIs - Clinical Protocol TP-000033 |
| 231202 | 50 | 53 | -3 | Beta Study of the Visby Sexual Health Test - Clinical Protocol TP-000516 |
| 230582 | 1000 | 593 | 407 | Disposition of BioRepository Samples - Lav/Yellow Tubes |
| 230530 | 20000 | 1295 | 18705 | Customer Samples kept in Biorepository (CMVG Samples, Susan Rimpel) |
| 230296 | 1 | 1 | 0 | WBC of 8000 to 10000 cells/ul or higher |
| 230007 | 30 | 30 | 0 | Prospective SARS-CoV-2 Negative Raw Saliva Samples - OR21-232 |
| 229502 | 400 | 402 | -2 | SARS-CoV-2 Fresh Negative Saliva Samples in 2 collection devices (SpeciMAX and Spectrum) + Raw Saliva Sample |
| 228847 | 1 | 1 | 0 | Pre-Selected HBV Samples from Inventory with Viral Load and Genotype |
| 228548 | 100 | 102 | -2 | Remnant VZV Samples (IGG Negative) |
| 228201 | 20000 | 466 | 19534 | Customer Samples kept in Biorepository from Minneapolis Medical Research Foundation (MMRF) |
| 227994 | 130 | 5 | 125 | PAS-19SUST054 - HCV |
| 227993 | 130 | 1 | 129 | PAS-19SUST052 - HBV |
| 227992 | 130 | 10 | 120 | PAS-18SUST041 - Evaluation of the BD Vacutainer® K2EDTA Blood Collection Tubes with Hemogard™ Closure using Molecular Diagnostic Testing for HIV-1 Viral Load (VL) Assay |
| 227629 | 50 | 8 | 42 | SARS-CoV-2 Positive NP and Saliva Matched Set |
| 227621 | 3 | 2 | 1 | HIV-1 Positive Prospective Blood Collection Protocol: - Three (3) D/Ps to have an HIV-1 Viral Load of: Donor #1: 1000 copies/mL (+/- 10%) Donor #2: 2000 copies/mL (+/- 10%) Donor #3: 3000 copies/mL (+/- 10%) |
| 227020 | 8 | 8 | 0 | Pre-Selected HIV Subtyped Samples from Inventory |
| 226510 | 300 | 299 | 1 | SARS-CoV-2 Fresh Negative Saliva Samples in 3 collection devices (Isohelix, SpeciMAX and Spectrum) + Raw Saliva Sample |
| 226001 | 100 | 37 | 63 | SARS-CoV-2 Positive Nasal, Oropharyngeal Dry Swab and Raw Saliva Collection Protocol |
| 225611 | 10000 | 0 | 10000 | A Multi Site, Longitudinal, Prospective Collection Protocol in order to obtain Samples from Normal Healthy D/Ps |
| 225101 | 1000 | 1 | 999 | COVID-19 Testing; Private Office |
| 224701 | 360 | 0 | 360 | cX8-COV-549: Classic Repro Protocol |
| 224534 | 180 | 124 | 56 | SARS-CoV-2 Negative NP and Raw Saliva Matched Set |
| 224514 | 600 | 76 | 524 | Initiative to Screen Potential Study Candidates (SUST) |
| 223768 | 12 | 12 | 0 | Remnant SARS-CoV-2 Positive Dry Nasal Swabs |
| 222843 | 20 | 0 | 20 | Remnant SARS-CoV-2 Positive Nasopharyngeal Swabs from Inventory |
| 222391 | 3 | 0 | 3 | Prospective Whole Blood Collection from HxV Negative D/Ps |
| 222390 | 6 | 6 | 0 | Prospective Whole Blood Collection from HxV Negative D/Ps |
| 221566 | 200 | 200 | 0 | SARS-CoV-2 Fresh Negative Saliva Samples in collection devices (SpeciMAX and Spectrum) + NP swab remnant |
| 220541 | 100 | 42 | 58 | Collection protocol for Panel construction (Custom HIV-1 Matched sets panels, Q_16913) |
| 219607 | 1000 | 9 | 991 | COVID-19 Testing; Private Office |
| 219219 | 22 | 21 | 1 | Normal Serum and Plasma Samples for Panels_Q_16894, Q_16914 and Q_16913 |
| 218357 | 325 | 473 | -148 | Prospective Healthy Subject Blood Collection Protocol |
| 217882 | 65 | 12 | 53 | Prospective SARS-CoV-2 Positive Sample Collection Protocol (NPS and Saliva) |
| 213622 | 2500 | 0 | 2500 | Protocol: cX8-CAB-547 - cobas® SARS-CoV-2 & Influenza A/B for Use on the cobas® 6800/8800 Systems: A Method Comparison Study |
| 210687 | 7 | 8 | -1 | Pre-Selected HCV Positive Samples from Inventory with HCV Viral Load and Genotype |
| 210071 | 2500 | 339 | 2161 | Protocol: cX8-CAB-533 - cobas® SARS-CoV-2 & Influenza A/B for Use on the cobas® 6800/8800 Systems: A Method Comparison Study |
| 208168 | 1000 | 111 | 889 | COVID-19 Testing; Private Office |
| 206253 | 60 | 20 | 40 | High Volume K2EDTA Whole Blood and Plasma from Healthy Donors |
| 205506 | 200 | 0 | 200 | Urine and Saliva Matched Set from Healthy D/Ps -100 subject collected in the morning until 9 AM -100 subjects collected in the afternoon after 4 PM |
| 205083 | 10 | 0 | 10 | Prospective Urine Collection from Healthy Donors |
| 204811 | 150 | 190 | -40 | SARS-CoV-2 Negative Raw Saliva Samples from Inventory |
| 204810 | 40 | 0 | 40 | Prospective SARS-CoV-2 Negative Raw Saliva Samples Ship same day |
| 204808 | 50 | 0 | 50 | SARS-CoV-2 Negative Nasal Swabs from Inventory |
| 203243 | 2000 | 0 | 2000 | Pre-Selected HxV Negative Samples from Inventory |
| 202732 | 1000 | 99 | 901 | PROTOCOL 274C3 - Clinical Evaluation of the Xpert® Xpress CoV-2/Flu/RSV XC Test on the GeneXpert Dx and Infinity Systems in Laboratory and Near-Patient Testing Environment |
| 201758 | 130 | 44 | 86 | PAS-18SUST033 - Validation of the Clinical Performance of BD Vacutainer® PPT™ Plasma Preparation Tube with Hemogard™ Closure in Comparison with the Greiner Vacuette® K2EDTA Gel Tubes for Molecular Diagnostic Testing using HIV-1 Viral Load (VL) Assay |
| 200508 | 1000 | 60 | 940 | COVID-19 Testing; Private Office |
| 198619 | 2 | 2 | 0 | HIV Viral Load Testing |
| 198618 | 1 | 1 | 0 | HCV Viral Load Testing |
| 198399 | 220 | 127 | 93 | Prospective SARS-CoV-2 Collection from Symptomatic D/Ps |
| 198391 | 500 | 0 | 500 | Prospective Healthy Subject Blood Collection Protocol |
| 197511 | 20 | 0 | 20 | SARS-CoV-2 Positive Serum and NPS Matched Set Samples from Inventory |
| 195801 | 220 | 0 | 220 | Prospective SARS-CoV-2 Collection from Symptomatic D/Ps |
| 195775 | 20000 | 1380 | 18620 | Customer Samples kept in Biorepository from HBcT2 [JRID#93116] |
| 195561 | 50 | 104 | -54 | SARS-CoV-2 RNA Hologic Testing |
| 195554 | 200 | 328 | -128 | SARS-CoV-2 RNA Hologic Testing |
| 194268 | 150 | 0 | 150 | Prospective Nasal Swab Collection Protocol |
| 194052 | 21 | 0 | 21 | HxV Negative K2EDTA Plasma from Inventory - SRF_TBA |
| 193266 | 200 | 130 | 70 | Prospective SARS-CoV-2 Collection from Symptomatic D/Ps |
| 191880 | 875 | 600 | 275 | Prospective Healthy Subject Blood Collection Protocol |
| 190737 | 5000 | 9 | 4991 | SARS-CoV-2 Survey (PT) |
| 184026 | 700 | 542 | 158 | SARS-CoV-2 RNA Hologic Testing |
| 182696 | 1000 | 355 | 645 | Protocol: COL-RESP-528 - Collection of Respiratory Swab Samples from Patients with Suspected Respiratory Tract Infections |
| 180141 | 15 | 15 | 0 | Normal Serum and Plasma Samples for Panels_Q_16847 |
| 179314 | 5 | 586 | -581 | Pre-Selected HBV Samples from Inventory with Viral Load |
| 178076 | 130 | 79 | 51 | PAS -19SUST046 - Evaluation of BD Vacutainer® PPT™ Plasma Preparation Tube with Hemogard™ Closure for Repeatability and Reproducibility of Molecular Diagnostic Testing using HIV-1 Viral Load (VL) Assay |
| 176622 | 10 | 0 | 10 | Normal Serum Samples with Unit Back-Ups DP willing to donate a Whole Blood Unit |
| 176111 | 25 | 0 | 25 | Prospective SARS-CoV-2 Collection from Symptomatic D/Ps - SRF_6026_Q16802 |
| 175884 | 500 | 97 | 403 | SARS-CoV-2 RNA Hologic Testing |
| 175792 | 10000 | 116 | 9884 | COVID-19 Testing; Tu Cara me Sue |
| 175398 | 10000 | 552 | 9448 | COVID-19 Testing; Crew-Royal Caribbean Cruises Ltd |
| 175121 | 1000 | 27 | 973 | CBC Initiative |
| 174026 | 1000 | 122 | 878 | COVID-19 Testing; Private Office |
| 173505 | 20 | 20 | 0 | SARS-CoV-2 Positive Nasopharyngeal Swabs from Inventory |
| 172886 | 1000 | 1018 | -18 | COVID-19 Testing; Private Office |
| 169711 | 400 | 398 | 2 | SARS-CoV-2, Nasal swab, Nasopharyngeal Swab, Oropharyngeal swab and Saliva |
| 169440 | 300 | 110 | 190 | Remnant Pregnancy Samples |
| 169439 | 100 | 258 | -158 | Remnant HSV Samples |
| 168884 | 50 | 0 | 50 | Evaluation of the prognostic performance of HostDx ViralSeverity to predict outcomes of SARS-CoV-2 |
| 168867 | 1000 | 310 | 690 | COVID-19 Testing; Private Office |
| 168264 | 10 | 10 | 0 | SARS-CoV-2 Negative Nasal, Nasopharyngeal Swab |
| 168078 | 50 | 2 | 48 | Prospective COVID-19 Positive Sample Collection Protocol (NPS and Raw Saliva) |
| 165868 | 1000 | 114 | 886 | COVID-19 Testing; Private Office |
| 164218 | 1000 | 404 | 596 | COVID-19 Testing; Private Office |
| 163904 | 1000 | 871 | 129 | COVID-19 Testing; Private Office |
| 162422 | 1000 | 75 | 925 | COVID-19 Testing; Private Office |
| 162417 | 35 | 34 | 1 | Fresh Whole Blood from Healthy (HxV Negative) D/Ps - SRF_5868_4 |
| 161853 | 100 | 861 | -761 | Abbott RealTime CT/NG Testing, Cepheid_248C1& 248C3 |
| 160615 | 47 | 47 | 0 | Clinical Performance of the Checkable Medical COVID-19 At-home Rapid Antibody Test and the Clarity COVIBLOCK COVID-19 IgG/IgM Antibody Test (Positive) |
| 160614 | 75 | 90 | -15 | Clinical Performance of the Checkable Medical COVID-19 At-home Rapid Antibody Test and the Clarity COVIBLOCK COVID-19 IgG/IgM Antibody Test (Negative) |
| 157934 | 1000 | 803 | 197 | COVID-19 Testing; Private Office |
| 156661 | 10000 | 1690 | 8310 | COVID-19 Testing; Private Office |
| 155679 | 30 | 310 | -280 | SARS-CoV-2 Positive Nasal, Oropharyngeal Dry Swab and Raw Saliva Collection Protocol |
| 154904 | 10000 | 40 | 9960 | COVID-19 Testing; Private Office |
| 154536 | 1000 | 458 | 542 | Cerebral Spinal Fluid (CSF) Unit from Live D/Ps - Minimum total volume of 500 ml required - Individual samples of at least 0.25 ml - The samples must have no trace of hemolysis (red color). - Stored under -80°C. - Remnant material acceptable - No IRB nor Informed Consent needed - No clinical history - Custom Manifest file |
| 153900 | 10000 | 31303 | -21303 | COVID-19 Testing, Florida Department of Health |
| 152854 | 10000 | 0 | 10000 | A Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from Normal Healthy D/Ps |
| 152825 | 5000 | 102044 | -97044 | COVID-19 Testing |
| 152764 | 9 | 27 | -18 | HCV Viral Load Testing |
| 152672 | 5000 | 40 | 4960 | Follow-UP_COVID-19 Testing_Blood and Nasopharyngeal Swabs |
| 152661 | 1000 | 41 | 959 | Collection protocol for Panel construction (Custom HIV-1 Matched sets panels, QT00016682) |
| 152645 | 24 | 0 | 24 | Female Vaginal Sample Collection Protocol for Panel Development |
| 152331 | 5000 | 1654 | 3346 | COVID-19 Testing |
| 151990 | 195 | 13 | 182 | Pre-Selected CMV Positive Samples form Inventory (SRF_5628 - STING Project) |
| 151989 | 195 | 50 | 145 | Pre-Selected CMV Negative Samples form Inventory (SRF_5628 - STING Project) |
| 151893 | 500 | 282 | 218 | Fresh Whole Blood, Capillary blood, Nasopharyngeal swab and Nasal swab match set from symptomatic individuals |
| 151886 | 500 | 285 | 215 | Fresh Whole Blood, Capillary blood, Nasopharyngeal swab and Nasal swab match set from symptomatic individuals |
| 151681 | 5000 | 3 | 4997 | Refer to Processing Instructions @ Attachment Tab |
| 151476 | 1 | 0 | 1 | HIV Group and Subtype Testing |
| 150014 | 500 | 64 | 436 | Seegene Validation Collection Protocol from Male and Female Samples |
| 149547 | 5000 | 180 | 4820 | Refer to Processing Instructions @ Attachment Tab TESTS TO SELECT PER LOCATION - REFER TO ATTACHMENT TAB |
| 149472 | 100 | 69 | 31 | HIV-2 Prospective Blood Collection Protocol - SRF_5628 |
| 149267 | 200 | 135 | 65 | Prospective Nasopharyngeal Swab Collection- SRF_5469 |
| 148791 | 5000 | 24 | 4976 | Refer to Processing Instructions @ Attachment Tab |
| 146391 | 92 | 0 | 92 | High Volume Whole Blood Collection to Evaluate The Long-Term Stability of Roche cfDNA tubes - SRF_5743 |
| 146000 | 520 | 282 | 238 | Prospective Nasal and Nasopharyngeal Matched Swab Sample Collection Protocol |
| 145574 | 5000 | 60 | 4940 | Refer to Processing Instructions @ Attachment Tab |
| 144888 | 195 | 1277 | -1082 | Pre-Selected Negative Samples form Inventory (SRF_5628 - STING Project (SRF_0002000)) |
| 144620 | 5000 | 29 | 4971 | Refer to Processing Instructions @ Attachment Tab |
| 144001 | 100 | 825 | -725 | Pediatric EBV Samples (Tested for EBV Early Ag, EBV Nuclear Ag, EBV VCA IgG and EBV IgM): - 50 samples from subjects with the ages of 2 through 12 years of age AND - 50 samples from subjects with the ages of 13 through 21 years of age - Gender: Male or Female - Minimum Volume: 1.5 mL (1.2 mL's) - Storage Temperature: Samples must have been frozen at -20°C or below within 2 days of collection. |
| 143401 | 1500 | 1158 | 342 | Cerebral Spinal Fluid (CSF) Unit from Live D/Ps - Minimum total volume of 3000 ml required - Individual samples of at least 0.25 ml - The samples must have no trace of hemolysis (red color). - Stored under -80°C. - Remnant material acceptable - No IRB nor Informed Consent needed - No clinical history - Custom Manifest file |
| 142755 | 5000 | 60 | 4940 | Refer to Processing Instructions @ Attachment Tab |
| 141914 | 1000 | 7 | 993 | HIV Initiative |
| 141834 | 1500 | 1246 | 254 | HIV-1 Viral Load Testing Proposal |
| 141493 | 5000 | 30 | 4970 | HCV Viral Load and Genotype Survey (PT) |
| 141491 | 5000 | 12 | 4988 | HBV Viral Load Survey (PT) |
| 141490 | 5000 | 30 | 4970 | HIV Viral Load Survey (PT) |
| 141142 | 50 | 12 | 38 | Fresh Whole Blood from Healthy (HxV Negative) D/Ps - SRF_5635 |
| 140923 | 5000 | 50 | 4950 | Refer to Processing Instructions @ Attachment Tab |
| 140922 | 5000 | 30 | 4970 | Refer to Processing Instructions @ Attachment Tab |
| 140530 | 5000 | 10 | 4990 | Rubella IgG (AAB - PT) |
| 140528 | 5000 | 6 | 4994 | ToRCH (AAB - PT) |
| 140300 | 1500 | 1500 | 0 | HIV-1 Viral Load Testing Proposal |
| 139409 | 5000 | 65 | 4935 | Pregnancy (PT) |
| 137933 | 5000 | 0 | 5000 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Cameroon |
| 137683 | 930 | 235 | 695 | Preeclampsia Blood Collection Protocol from Asymptomatic and Symptomatic Populations |
| 136025 | 300 | 357 | -57 | EBV Samples (Tested for EBV Early Ag, EBV Nuclear Ag, EBV VCA IgG and EBV IgM) |
| 135041 | 100 | 0 | 100 | GC/CT/MG/TV prospective collection at Budapest |
| 134700 | 60 | 25 | 35 | Abbott Real Time EBV and BKV Testing - SRF_5465 |
| 134182 | 100 | 80 | 20 | HBV/Mayaro Samples from Colombia |
| 133225 | 200 | 274 | -74 | Prospective HCV Positive serum collection |
| 129688 | 200 | 123 | 77 | EBV / EBK Samples from National Center of Urology - Tbilisi, Georgia |
| 129538 | 1000 | 309 | 691 | RPR Initiative |
| 128402 | 1000 | 64 | 936 | CBC Initiative |
| 124266 | 5000 | 143 | 4857 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Cote D'Ivoire |
| 122931 | 5000 | 1510 | 3490 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella |
| 122654 | 5000 | 171 | 4829 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Swaziland |
| 120851 | 140 | 26 | 114 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV |
| 120409 | 300 | 84 | 216 | Matched Prospective Collection Protocol from an HCV, HBsAg and/or RPR Positive Reactive Population |
| 109382 | 100 | 32 | 68 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV |
| 109381 | 300 | 6 | 294 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV |
| 108692 | 1000 | 939 | 61 | HxV Testing Initiative |
| 102772 | 50 | 26 | 24 | Random Cadaveric Samples |
| 102419 | 1000 | 445 | 555 | Samples on hold for future shipments to China |
| 98830 | 10000 | 0 | 10000 | A Multi-Site, Multi-Point, Prospective Collection Protocol in order to obtain PAP, Endocervical Swab, Vaginal Swab, Nasal Swab, Pharyngeal Swab, Rectal Swab, Urethral Swab and/or Urine Samples |
| 98084 | 1000 | 562 | 438 | CBC Qualifying Job Request |
| 96278 | 5000 | 185 | 4815 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella |
| 96055 | 40 | 1628 | -1588 | Hologic Panels for HIV and HCV |
| 94841 | 500 | 1 | 499 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV - LGR |
| 93116 | 700 | 734 | -34 | Prospective Blood Collection Protocol from D/Ps with Signs & Symptoms or at High Risk for Hepatitis |
| 80997 | 5000 | 428 | 4572 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Cameroon |
| 79734 | 100 | 0 | 100 | Prospective Zika Screening and Longitudinal Sample Collection Protocol |
| 78138 | 300 | 140 | 160 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV |
| 78137 | 300 | 414 | -114 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV |
| 74261 | 10000 | 0 | 10000 | A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella |
| 68258 | 10000 | 0 | 10000 | A Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from Normal Healthy D/Ps |
| 66495 | 200 | 225 | -25 | Prospective Blood Collection Protocol in order to Collect Samples from Donor/Participants (D/Ps) in Low Socio-Economic Regions of the World for Dengue |
| 63869 | 1 | 2 | -1 | Negative Material for Panel Member |
| 63868 | 1000 | 555 | 445 | Blinded HIV/HBV/HCV Prospective Blood Collection Protocol from Guinea Bissau |
| 56717 | 20000 | 0 | 20000 | A Multi-Site, Multi-Point, Prospective Collection Protocol in order to obtain PAP , Endocervical, Vaginal, Nasal and/or Urine Samples |
| 55075 | 10000 | 28 | 9972 | Beta HCG Matched Set Prospective Blood Collection Protocol |
| 54664 | 200 | 148 | 52 | Random Cadaveric Samples |
| 38626 | 300 | 143 | 157 | Prospective Sample Collection of Specifically Diagnosed D/Ps with Diseases of the Liver or Related Complications: ·50 x Alcoholic liver disease ·30 x Autoimmune hepatitis ·30 x Fatty liver disease ·30 x Non-alcoholic Steatohepatitis (NASH) ·30 x Primary Biliary Cirrhosis (PBC) |
| 27615 | 15000 | 633 | 14367 | Prospective Blood Collection Protocol in order to Collect Samples from Donor/Participants (D/Ps) in Low Socio-Economic Regions of the World |
| 26761 | 10000 | 482 | 9518 | HIV Positive Time Stability Whole Blood Collection Protocol |
| 10694 | 3000 | 2234 | 766 | HCV Longitudinal Prospective Blood Collection Protocol |
| 10693 | 3000 | 369 | 2631 | HBV Multi-Point Prospective Blood Collection Protocol |
| 8568 | 300 | 1528 | -1228 | Positive Plasma Units from Blood Centers Around the World (HIV, HBsAg & HCV) |
BCW helps clinicians during their research process through collection sites and D/P availability. Our collection sites have been duly inspected and adhere to our Good Manufacturing Practices thus ensuring reliability during the collection process. In addition to this we provide training seminars as part of our Quality Assurance in order to maintain the level of quality that our customers are accustomed to.
You will be invited to participate in research studies for the advancement of diagnostic technologies. Participation in these studies is voluntary. Our D/P's are informed of what the research projects are about and are given an Informed Consent, which evidences their willingness to participate. In order to protect our D/P's we never divulge your identity to the research facilities thus guaranteeing D/P confidentiality.
